Over the years, minority input in the clinical development of life-saving drugs has been lacking, particularly when it comes to clinical trial participation. That has led to disparities in the efficacy of medications when taken by minority
Discovery Labs suburban Philadelphia campus gained a new tenant, the University of Pennsylvania Gene Therapy Program (GTP), which focuses on the development of AAV-based gene therapies for rare and orphan genetic diseases with high unmet needs.
ThruPore Technologies Inc., a market-disrupting, woman-led company with locations in Delaware and Alabama that is known for its Dr. Filter product, has chosen Newark as its site for expansion and continued innovation in chemistry and air filtration.
Philadelphia’s soaring life sciences commercial real estate market is being driven by the combination of strong demand for advanced lab and manufacturing facilities and near record low vacancy rates.
Gyroscope Therapeutics, a gene therapy company developing treatments for eye diseases, filed a Form F-1 with the U.S. Securities and Exchange Commission announcing its intention to begin selling American Depository Shares on the Nasdaq Exchange under the ticker symbol “VISN.” At the time of its filing this week, Gyroscope said it has not yet set the pricing terms for its stock. The $100 million is a placeholder figure. Based on positive clinical activity, and a recent financing round, the company is likely to raise significantly more than $100 million.
Code Biotherapeutics, a gene therapy company taking aim at rare diseases such as Duchenne Muscular Dystrophy, launched into the Greater Philadelphia gene therapy epicenter with $10 million in seed financing.
Robust Investment in Greater Philadelphia Region’s Cell and Gene Therapy Sector Continued in the First Quarter of 2021 PHILADELPHIA (April 8, 2021) – The robust venture capital funding the Greater [….]
The Discovery Labs’ 2.4 million square foot site in King of Prussia, PA provides all the necessary ingredients to accelerate speed to market for cell and gene therapy innovators. The Center for Breakthrough Medicines is a cell and gene therapy contract development and manufacturing organization (CDMO) for plasmid DNA, viral vectors, and cellular therapy products and is located on-site.
As some are now calling it, the greater Philadelphia region, or ‘Cellecon Valley, is garnering a lot of attention these days as a rapidly emerging Biopharma cluster, earning a defining spot among the top 10 clusters in the US.
Life Science Cares Philadelphia launched Project Onramp Philadelphia, a program aimed at connecting economically disadvantaged college students with paid summer internships at life science companies based in the area.
